12 results
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
during the year ended December 31, 2023 are as follows:
R&D Category
Expense
R&D consultants
0.25 million
R&D research
0.37 million
R&D toxicology
0.21 … million
R&D stock compensation
0.74 million
Liquidity and Capital Resources
Since our inception in September 2020, we have financed our operations
10-Q
2023 Q2
MIRA
Mira Pharmaceuticals Inc
15 Sep 23
Quarterly report
4:45pm
million of the net proceeds to fund preclinical toxicology studies and R&D consultants, $0.7 million in general and administrative expenses and $1
424B4
MIRA
Mira Pharmaceuticals Inc
4 Aug 23
Prospectus supplement with pricing info
1:01pm
during 2022. Major components of research and development expenses during the three months ended March 31, 2023 are as follows:
R&D Category
Expense …
Toxicology
0.15 million
R&D consultants
0.01 million
R&D laboratory costs
0.01 million
R&D stock compensation
0.09 million
Results of Operations
424B1
yg532t
4 Aug 23
Prospectus with pricing info
12:59pm
S-1
dv9mk
29 Jun 23
IPO registration
4:39pm
DRSLTR
d6chwu
8 Jun 23
Correspondence regarding draft registration statement
12:00am
DRS/A
5p3rd78yy66m 32
8 Jun 23
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next